Dec 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' LXRX.O add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
(Reporting by Puyaan Singh and Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.